Alergia e Imunologia
[Preprint] Estudo RECOVERY descobre que a combinação de anticorpo monoclonal Regeneron reduz as mortes de pacientes hospitalizados com COVID que não desenvolveram sua própria resposta imunológica.
17 Jun, 2021 | 11:04hComunicado de imprensa: RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response
Estudo original (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv
Comentários: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science E Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP E Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT E Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre
Comentário no Twitter
RECOVERY Pre-print:
In patients hospitalised with COVID-19 but no natural antibody response, monoclonal antibody infusion:
– reduced mortality
– increased speed of discharge
– reduced progression to invasive mechanical ventilation or deathhttps://t.co/rpDk4eUhmm pic.twitter.com/wXegKcDZg8— Martin Landray (@MartinLandray) June 16, 2021
Série de casos | 7 casos de miocardite após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 11:00hMyocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation
Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Série de casos | Achados clínicos e de ressonância magnética em 4 casos de miocardite após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 10:58hComentário: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology
Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Série de casos | Miocardite sintomática aguda em 7 adolescentes após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 10:57hRelacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Perspectiva de longo prazo sobre a imunidade à COVID – “Estudos clínicos agora indicam que a imunidade é de longa duração.”
16 Jun, 2021 | 10:52hA long-term perspective on immunity to COVID – Nature
[Comunicado de imprensa – Ainda não publicado] Vacina da Novavax contra COVID-19 demonstra 90% de eficácia geral e 100% de proteção contra doença moderada e grave.
15 Jun, 2021 | 11:35hComunicado de imprensa: Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Comentários: U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 – NIH News Releases E Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show – STAT E Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply – Science E Novavax COVID vaccine 90% effective in phase 3 trial – CIDRAP E What the Novavax vaccine means for the global fight against Covid-19 – Vox
Comentário no Twitter (fio – clique para saber mais)
Good news—Novavax protein-subunit vaccine phase 3 trial shown to to be 90.4% effective overall, 100% against moderate to severe disease. This is different type from mRNA and from AZ/J&J adenovirus vaccines, and different from inactivated types. #COVID19 https://t.co/ajoGhaOUu9
— Eric Feigl-Ding (@DrEricDing) June 14, 2021
[Preprint] 2 doses de vacina contra Covid (Pfizer-BioNTech ou Oxford-AstraZeneca) são altamente eficazes contra hospitalização decorrente de infecção pela variante Delta.
15 Jun, 2021 | 11:32hComunicado de imprensa: Vaccines highly effective against hospitalisation from Delta variant – Public Health England
Preprint: Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant
Comentário no Twitter
NEWS — Our new analysis shows for the first time that two doses of the #COVID19 #vaccines are highly effective against hospitalisation from the #Delta (B.1.61.2) #variant.
Read more: https://t.co/6z67CW85Zw pic.twitter.com/oyRFghHpXw
— Public Health England (@PHE_uk) June 14, 2021
Série de casos | Segurança e imunogenicidade de uma terceira dose de vacina contra SARS-CoV-2 em transplantados receptores de órgãos sólidos.
15 Jun, 2021 | 11:24hComentários: For Transplant Recipients, Third Time May Be the Charm for Better COVID Vaccine Protection – Hopkins Medicine E Extra COVID Vaccine May Help Protect Transplant Patients – Associated Press
Comentário no Twitter
Our report about 3rd vaccine doses in transplant patients is published! "It is encouraging that antibody titers increased after the 3rd dose in 1/3 of patients who had negative antibody titers and in all patients who had low-positive antibody titers"https://t.co/6XElwyIdAa
— Dorry Segev (@Dorry_Segev) June 14, 2021
Pesquisa em laboratório mostra que o soro de pessoas plenamente vacinadas (após 2 doses) com a vacina da Pfizer–BioNTech pode neutralizar efetivamente a variante B.1.617 (Delta) e outras do SARS-CoV-2.
14 Jun, 2021 | 11:24hBNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants – Nature
Comentário no Twitter
An in-vitro study of sera from persons fully vaccinated with the Pfizer-BioNTech vaccine found that all samples neutralized SARS-CoV-2 virus variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.618 and B.1.525. https://t.co/7lXCVe7sPY
— Carlos del Rio (@CarlosdelRio7) June 12, 2021
Sinopse | Atualizações das diretrizes de tratamento da asma pediátrica.
8 Jun, 2021 | 10:22hUpdates to the Pediatrics Asthma Management Guidelines – JAMA Pediatrics (gratuito por tempo limitado)